Your browser doesn't support javascript.
loading
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
Bavetsias, Vassilios; Lanigan, Rachel M; Ruda, Gian Filippo; Atrash, Butrus; McLaughlin, Mark G; Tumber, Anthony; Mok, N Yi; Le Bihan, Yann-Vaï; Dempster, Sally; Boxall, Katherine J; Jeganathan, Fiona; Hatch, Stephanie B; Savitsky, Pavel; Velupillai, Srikannathasan; Krojer, Tobias; England, Katherine S; Sejberg, Jimmy; Thai, Ching; Donovan, Adam; Pal, Akos; Scozzafava, Giuseppe; Bennett, James M; Kawamura, Akane; Johansson, Catrine; Szykowska, Aleksandra; Gileadi, Carina; Burgess-Brown, Nicola A; von Delft, Frank; Oppermann, Udo; Walters, Zoe; Shipley, Janet; Raynaud, Florence I; Westaway, Susan M; Prinjha, Rab K; Fedorov, Oleg; Burke, Rosemary; Schofield, Christopher J; Westwood, Isaac M; Bountra, Chas; Müller, Susanne; van Montfort, Rob L M; Brennan, Paul E; Blagg, Julian.
Afiliação
  • Bavetsias V; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Lanigan RM; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Ruda GF; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Atrash B; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K.
  • McLaughlin MG; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Tumber A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Mok NY; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Le Bihan YV; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K.
  • Dempster S; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Boxall KJ; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Jeganathan F; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Hatch SB; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Savitsky P; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Velupillai S; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Krojer T; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K.
  • England KS; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Sejberg J; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Thai C; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Donovan A; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Pal A; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K.
  • Scozzafava G; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Bennett JM; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Kawamura A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Johansson C; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Szykowska A; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Gileadi C; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K.
  • Burgess-Brown NA; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • von Delft F; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford , NDMRB Roosevelt Drive, Oxford OX3 7FZ, U.K.
  • Oppermann U; Chemistry Research Laboratory, University of Oxford , Mansfield Road, Oxford OX1 3TA, U.K.
  • Walters Z; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Shipley J; Botnar Research Centre, NIHR Oxford Biomedical Research Unit , Oxford OX3 7LD, U.K.
  • Raynaud FI; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Westaway SM; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Prinjha RK; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Fedorov O; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Burke R; Diamond Light Source (DLS), Harwell Science and Innovation Campus , Didcot OX11 0DE, U.K.
  • Schofield CJ; Department of Biochemistry, University of Johannesburg , Auckland Park 2006, South Africa.
  • Westwood IM; Structural Genomics Consortium (SGC), University of Oxford , ORCRB Roosevelt Drive, Oxford OX3 7DQ, U.K.
  • Bountra C; Botnar Research Centre, NIHR Oxford Biomedical Research Unit , Oxford OX3 7LD, U.K.
  • Müller S; Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research , London SM2 5NG, U.K.
  • van Montfort RL; Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research , London SM2 5NG, U.K.
  • Brennan PE; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research , 15 Cotswold Road, London SM2 5NG, U.K.
  • Blagg J; Epinova Discovery Performance Unit, Medicines Research Centre, GlaxoSmithKline R&D , Stevenage SG1 2NY, U.K.
J Med Chem ; 59(4): 1388-409, 2016 Feb 25.
Article em En | MEDLINE | ID: mdl-26741168
ABSTRACT
We report the discovery of N-substituted 4-(pyridin-2-yl)thiazole-2-amine derivatives and their subsequent optimization, guided by structure-based design, to give 8-(1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidin-4(3H)-ones, a series of potent JmjC histone N-methyl lysine demethylase (KDM) inhibitors which bind to Fe(II) in the active site. Substitution from C4 of the pyrazole moiety allows access to the histone peptide substrate binding site; incorporation of a conformationally constrained 4-phenylpiperidine linker gives derivatives such as 54j and 54k which demonstrate equipotent activity versus the KDM4 (JMJD2) and KDM5 (JARID1) subfamily demethylases, selectivity over representative exemplars of the KDM2, KDM3, and KDM6 subfamilies, cellular permeability in the Caco-2 assay, and, for 54k, inhibition of H3K9Me3 and H3K4Me3 demethylation in a cell-based assay.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinonas / Proteínas Repressoras / Proteínas Nucleares / Inibidores Enzimáticos / Histona Desmetilases com o Domínio Jumonji Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinonas / Proteínas Repressoras / Proteínas Nucleares / Inibidores Enzimáticos / Histona Desmetilases com o Domínio Jumonji Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article